New: Our latest case study on qFibrosis' role in the successful development of Rezdiffra

EASL 2024
Breakfast Meeting

5th Jun 2024
8 – 10am CEST

Stay up-to-date with the latest research

This year, our Breakfast Meeting at EASL will focus on the cutting-edge advances in AI digital pathology in MASH and MASLD clinical trials. We have an exciting lineup of presentations and an interactive session with expert panelists, who will share their insights and experiences into management of MASH patients and future clinical trial design in the post-drug approval era. 

Attendees will have the opportunity to:

  • Learn about the latest AI digital pathology tools for the assessment of pharmacodynamic responses in liver biopsies during MASH clinical trials
  • Understand how we can use measures of spatial-based morphology and features of fibrosis that correlate to patients’ clinical outcomes
  • Engage in a thought-provoking panel discussion on the role of liver biopsies in clinical practice and future trials in MASH post-drug approval

Moderated by

Nikolai Naoumov MD, PhD, FRCP, FRCPath, FAASLD
Professor of Hepatology Royal College of Physicians (London)

Event Speakers

Arun Sanyal MD
Professor of Medicine and Director at VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Jonathan Fallowfield BSc (Hons), BM (Hons), PhD
Personal Chair of Translational Liver Research at University of Edinburgh
Timothy Kendall BM, PhD, FRCPath
Senior Clinical Fellow in Pathology & Honorary Consultant Histopathologist at University of Edinburgh
Dean Tai PhD
Co-founder and Chief Scientific Officer at HistoIndex

Highlights from 2023 AASLD

Accepted presentations

Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH
Time and Location: Friday, 7 June, 5:15 – 5:30 PM, Gold Room
Presenter: Dr. Jörn M Schattenberg
Presentation ID: OS-124

Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution allowing direct clinical outcome prediction in MASLD
Time and Location: Friday, 7 June, 5:45 – 6:00 PM, Space 1+2
Presenter: Dr. Timothy Kendall
Presentation ID: OS-087
Poster Tour
qBallooning: AI-based ballooned hepatocyte detection and quantification by second harmonic generation/two photon excitation microscopy
Time and Location: Saturday, 8 June, 12:15 AM – 12:22 PM, Track Hub: Metabolism, Alcohol & Toxicity
Presenter: Dr. Dean Tai
Poster Number: FRI-208

Poster Presentations
Assessment of fibrosis change rates in placebo arm of metabolic dysfunction-associated steatohepatitis drug trials based on pathologist readouts and qFibrosis continuous values
Time and Location: Wednesday, 5 June, Poster Area
Poster Number: WED-213

AI digital pathology unmasked the “No Change” in conventional pathological assessment of MASLD patients with one year lifestyle intervention in a prospective cohort study
Time and Location: Wednesday, 5 June, Poster Area
Poster Number: WED-319

Validation of optimal liver biopsy size for reliable quantitation of fibrosis severity in different areas and structures of liver lobule using second harmonic generation microscopy with artificial intelligence analyses
Time and Location: Friday, 7 June, Poster Area
Poster Number: FRI-203

Regional fibrosis progression analysed by digital pathology with artificial intelligence is associated with renal dysfunction
Time and Location: Friday, 7 June, Poster Area
Poster Number: FRI-267

Genetic determinants of disease progression in metabolic dysfunction-associated liver disease patients unresponsive to lifestyle intervention: implications for personalized medicine
Time and Location: Friday, 7 June, Poster Area
Poster Number: TOP-310